Call Today for a FREE Confidential Case Review - Toll-Free 24/7 (866) 920-0753

Lamictal Lawsuit

Lamictal Lawsuit

The anti-seizure drug Lamictal carries a Boxed Warning about the risk of deadly allergic skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

What You Can Do & How We Can Help

The Schmidt Firm, PLLC is currently accepting Lamictal induced injury cases in all 50 states. If you or somebody you know has been diagnosed with SJS, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.

What is Lamictal?

Lamictal (lamotrigine) is a prescription medication that is used to prevent seizures in people with epilepsy. It was approved by the FDA in 1994 and is sold by GlaxoSmithKline (GSK). Lamictal is now available as a generic drug. There are several versions, including extended-release (Lamictal XR), an orally-disintegrating tablet (Lamictal ODT), and a chewable tablet (Lamictal CD).

Lamictal Stevens-Johnson Syndrome

The label on Lamictal includes a prominent Black Box Warning about the risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These severe rashes are estimated to affect one in 1,000 adults and up to 1 in 50 children.

SJS / TEN cause the epidermis (top layer of skin) to blister and peel off in large sheets. These rashes are extremely disfiguring, painful, and almost always must be treated with intensive care. They can also lead to life-threatening infections or other complications.

Most cases of Stevens-Johnson Syndrome from Lamictal occurred within 2-8 weeks of treatment, although rare cases have occurred up to 6 months later. Doctors should discontinue patients on Lamictal at the first sign of a rash unless the rash is clearly not caused by Lamictal.

Symptoms & Risks of SJS

  • Flu-like illness
  • Skin rash that spreads
  • Blisters
  • Inflammation of mucous membranes (eyes, mouth, genitals, etc.)
  • Persistent fever
  • Skin lesions
  • Sore mouth and throat
  • Vision loss or blindness
  • Infections
  • Pneumonia
  • Organ damage
  • Death

FDA Warning: Lamictal and Aseptic Meningitis

In August 2010, the FDA issued a Safety Alert about the risk of aseptic meningitis from Lamictal. This rare but life-threatening side effect occurs when the meninges (protective membrane covering the brain and spinal cord) becomes inflamed. It is likely caused by an allergic reaction (hypersensitivity).

Lamictal was associated with 40 cases of aseptic meningitis from December 1994 to November 2009. Symptoms occurred as little as one day after starting Lamictal, but an average of 16 days. One patient died and 35 were hospitalized. When doctors re-started patients on Lamictal, 15 developed severe symptoms within 30 minutes to 24 hours.

Do I have a Lamictal Lawsuit?

The Schmidt Firm, PLLC is currently accepting Lamictal induced injury cases in all 50 states. If you or somebody you know has been diagnosed with SJS, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.

Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.

Free Case Evaluation

The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs’ law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm’s reputation for providing personal attention to each and every client we represent.

No matter what type of case you have, you may contact us with confidence by filling out the email contact form below or calling us directly by dialing toll free 24 hrs/day (866) 920-0753.

*
*
*